Wegovy cost guide · 2026 prices · Updated 11 May 2026
Wegovy Cost Australia 2026: Price, BMI Eligibility, Telehealth vs In-Person
Wegovy (semaglutide 2.4mg) is the TGA-registered weight-loss formulation of semaglutide — same active molecule as Ozempic at a higher weight-loss-optimised dose. Wide availability in Australia since 2024. Not on the PBS for weight loss — patients pay private price $330-$450/month indefinitely. This guide covers cost, dose escalation, BMI eligibility, and how Wegovy compares to alternatives.
★Key takeaways
- ✓Wegovy is NOT on the PBS for weight loss. Private price: $330-$450/month telehealth, $250-$380/month via your own GP.
- ✓TGA-registered for BMI 30+ or BMI 27+ with weight-related comorbidity. Same active molecule as Ozempic at higher weight-loss dose.
- ✓Average weight loss: ~15% body weight at 68 weeks (STEP-1 trial). 70-85% of patients lose 10%+ of body weight.
- ✓Dose escalation 17 weeks: 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg/week (maintenance). Side effects most pronounced first 4-8 weeks.
- ✓~2/3 of weight regained within 12 months of stopping without intensive lifestyle change. Most patients remain on Wegovy indefinitely.
| Provider ⇅ | Monthly cost ⇅ | Includes ⇅ | Eligibility ⇅ | Notes ⇅ |
|---|---|---|---|---|
| Telehealth subscription (Juniper / Mosh / Pilot / Compass) | $330-$450/month | Consult + script + admin + shipping | BMI 30+ or 27+ comorbidity | Fastest onboarding |
| In-person medical weight-loss clinic | $280-$400/month + program fee | Comprehensive metabolic work-up | Same BMI criteria | Best for comorbidities |
| Your own GP + pharmacy | $250-$380/month script | + GP consultation (Medicare-rebated) | GP willing to prescribe | Cheapest ongoing care |
Wegovy is NOT on the PBS for weight loss. All pathways are private price. Telehealth subscription is convenience-priced; your own GP is the cheapest ongoing pathway.
| Provider ⇅ | Dose ⇅ | Effect ⇅ | Notes ⇅ |
|---|---|---|---|
| Week 1-4 (initiation) | 0.25mg/week | Lowest dose, minimal effect | Tolerance establishment |
| Week 5-8 | 0.5mg/week | Early weight loss | Manage nausea |
| Week 9-12 | 1.0mg/week | Sustained weight loss | Continue titration |
| Week 13-16 | 1.7mg/week | Approaching target | Side effects ease |
| Week 17+ (maintenance) | 2.4mg/week | Maximum efficacy | Long-term dose |
Standard titration over 17 weeks reduces nausea incidence. Some patients tolerate faster titration; others require slower. Maintenance dose 2.4mg/week long-term.
Why Wegovy is the new weight-loss benchmark
Before Wegovy's TGA approval, GLP-1 weight-loss prescribing in Australia was off-label use of Ozempic (lower-dose semaglutide registered for diabetes only). Wegovy is the dedicated weight-loss formulation — same molecule, higher dose, registered for that indication. This means: (1) clear clinical pathway, (2) consistent dosing protocols, (3) eliminates the supply-priority issue (Ozempic supply is rationed for T2D patients).
STEP-1 trial published 2021: 14.9% mean body weight loss at 68 weeks vs 2.4% placebo. STEP-4 extension: weight loss is maintained while on medication; ~2/3 regained within 12 months of stopping without lifestyle change. Cardiovascular outcomes data from SELECT trial (2023): semaglutide reduced major adverse cardiovascular events by 20% in overweight/obese patients with established cardiovascular disease.
PBS status (and why Wegovy isn't subsidised)
As at January 2026, Wegovy is NOT on the PBS for weight loss. The PBS subsidises Ozempic (lower-dose semaglutide) only for type 2 diabetes, on Authority Streamlined criteria. The reason: PBS uses cost-effectiveness analysis (incremental cost per QALY), and the cost-effectiveness ratio for chronic GLP-1 weight-loss therapy is not currently within PBS willingness-to-pay range without significant price discount from Novo Nordisk.
PBAC submissions for weight-loss GLP-1 indications continue. If PBS listing happens, it would likely be restricted to higher-BMI patients (40+) with specific comorbidities. Patients should not assume PBS listing in the near term and budget for private cost.
How Wegovy compares to Mounjaro
Mounjaro (tirzepatide) is a newer dual-agonist (GLP-1 + GIP) with stronger published weight-loss outcomes — SURMOUNT-1 trial: ~21% body weight loss at 72 weeks (highest dose) vs Wegovy ~15%. Similar side-effect profile + cost ($330-$450/month). Many prescribers now prefer Mounjaro for new starters where maximum weight-loss is the priority.
Wegovy advantages: longer clinical track record, more cardiovascular outcomes data, broader prescriber familiarity. Mounjaro advantages: stronger weight-loss outcomes, slightly less GI side effects in some patients.
Common questions
How much does Wegovy cost in Australia in 2026?
Wegovy is NOT on the PBS for weight loss in Australia. Private cost: $330-$450/month via telehealth subscription (includes consult + script + admin + shipping), or $250-$380/month script via your own GP + pharmacy + Medicare-rebated consultations. Annual cost: ~$3,500-$5,400. Significantly more expensive than Ozempic for T2D patients ($380/year via PBS) but Wegovy is the official weight-loss indication.
Is Wegovy on the PBS in Australia?
No. As at January 2026, Wegovy is NOT on the PBS for weight loss. The PBS subsidises Ozempic (lower-dose semaglutide) for type 2 diabetes only. Patients pay the full private price for Wegovy indefinitely. PBS listing for weight-loss indications is under active PBAC consideration but no listing as at writing.
Am I eligible for Wegovy?
TGA-registered for: BMI 30+ kg/m² (Class I obesity or above), OR BMI 27-29.9 with at least one weight-related comorbidity (hypertension, dyslipidaemia, type 2 diabetes, sleep apnoea, cardiovascular disease, fatty liver). Telehealth platforms typically apply these criteria strictly. In-person clinics may extend to BMI 25+ with multiple comorbidities at clinical discretion.
What's the difference between Wegovy and Ozempic?
Same active ingredient (semaglutide) but Wegovy is dosed higher (2.4mg) and registered for weight loss. Ozempic comes in 0.25mg, 0.5mg, 1mg, 2mg doses for type 2 diabetes. Wegovy: ~15% body weight loss at 68 weeks (STEP-1 trial). Ozempic 1mg: ~10% body weight loss. Wegovy is the optimal weight-loss tool; Ozempic is the diabetes tool that incidentally drops weight.
How much weight will I lose on Wegovy?
STEP-1 trial (semaglutide 2.4mg): 14.9% mean body weight loss at 68 weeks. Individual response varies — 70-85% of patients lose 10%+ of body weight; 5-15% are non-responders (lose <5% and considered for switch to Mounjaro or surgical pathway). STEP-4 trial extension: maintained weight loss requires ongoing medication or intensive lifestyle change.
How long does it take to feel effects?
Appetite suppression typically noticeable within 1-2 weeks of starting. Visible weight loss usually starts around week 4-8 as you titrate up dose. Maximum weight-loss rate around week 16-32 (mid-titration to maintenance). Plateau common around month 12-18 as body adjusts.
What are the most common side effects?
In first 4-8 weeks during dose escalation: nausea (40-60%), constipation, diarrhoea, fatigue, decreased appetite. Slower titration reduces these. Less common: gallstones (with rapid weight loss), pancreatitis (rare), gastroparesis (delayed stomach emptying). Theoretical medullary thyroid cancer warning from rodent studies — human data has not shown elevated risk.
Can I get Wegovy through Medicare?
Indirectly. The medication itself is NOT subsidised (private price $250-$450/month). However, your GP consultations to prescribe + monitor Wegovy ARE Medicare-rebated. Allied health visits (dietitian, psychology) under a Chronic Disease Management Plan or Mental Health Care Plan are also Medicare-rebated.
How does Wegovy compare to bariatric surgery?
Bariatric surgery (sleeve gastrectomy) produces 60-70% excess weight loss at 5 years vs Wegovy ~15% body weight at 1 year. Surgery is durable; Wegovy requires ongoing medication. Surgery $13,000-$25,000 one-off OOP; Wegovy $3,500-$5,400/year ongoing. For BMI 40+ or BMI 35+ with T2D, surgery typically outperforms long-term. For BMI 30-40 without major comorbidities, Wegovy is appropriate first-line.
Can I stop Wegovy and keep the weight off?
Most patients regain a significant portion. STEP-4 extension: approximately 2/3 of weight lost was regained within 12 months of stopping semaglutide without intensive lifestyle change. Many patients remain on Wegovy indefinitely or transition to bariatric surgery for durable weight loss.
Next step
Use our BMI + pathway calculator to check eligibility, then browse telehealth Wegovy providers or in-person clinics.